Xcout Intel
DiogenX
DiogenX is a preclinical-stage biotechnology company headquartered in Marseille, France, with research laboratories in Nice, dedicated to developing novel treatments for diabetes.
Subscribe to see DiogenX’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
DiogenX at a glance
DiogenX is a biotechnology company headquartered in France. Its most recent funding round, Series A, raised $29.7M in May 2023. Xcout tracks 2 named people at DiogenX, including Benjamin Charles (CEO).
DiogenX leadership
- Benjamin CharlesCEO
- Eleanor L. RamosIndependent Member of its Board of Directors
DiogenX funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $29.7M | 6 named | |
| Seed | $4.9M | 7 named | |
| Seed | $4.9M | 3 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
DiogenX competitors
A few of DiogenX's closest competitors — see the full list of competitors and alternatives →
Adocia is a clinical-stage biotechnology company that develops innovative formulations of proteins, peptides, and metabolic hormones. The company specializes in creating treatments for diabetes and obesity, as well as immunoprotective scaffolds for cell therapies.
AdipoPharma is a French biotech company dedicated to understanding the role of adipocyte cells in diabetes, focusing on lipid biosynthesis and whole-body metabolic health.
Paulex Bio Inc. is a biotechnology company headquartered in San Diego, California, focused on transformative treatments for type 1 and type 2 diabetes. Its lead approach targets beta cell regeneration through an oral administration.
Vogenx, Inc. is a clinical-stage biopharmaceutical and life science company that discovers and develops novel therapeutics to treat metabolic and gastrointestinal diseases, including post-bariatric hypoglycemia and gastroparesis. Its lead drug candidate, mizagliflozin, is an oral small molecule designed to inhibit SGLT1, reducing glucose absorption and the secretion of insulin and gastric inhibitory peptide.
Get DiogenX's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on DiogenX in Xcout Intel
- 2 named people with titles, LinkedIn and board committees
- 3 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access